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Methods
Heartworm-free mongrel dogs (25-30 kg) of either sex were anesthetized with pentobarbital sodium (30 mg/kg intravenous injection; Fort Dodge Laboratories, Inc., Fort Dodge, Iowa) and exsanguinated via the carotid arteries. The chest was quickly opened, and the heart was harvested and immersed in cool, oxygenated physiological salt solution of the following composition (mM): NaCl 118. 3 Ca-EDTA 0.016, and glucose 11.1 (control solution). The procedures and handling of the animals were reviewed and approved by the Institutional Animal Care and Use Committee of the Mayo Foundation.
In vitro experiments -Canine left circumflex coronary arteries were dissected free of connective tissue and placed in the oxygenated physiological salt solution. Segments (4-5 mm in length) of blood vessel were prepared with special care not to touch the intimal surface. In some of the segments in which vascular smooth muscle function was to be tested without the influence of the endothelium, the intimal surface was removed by gently rubbing the inner surface of the blood vessel with a pair of watchmaker forceps. This procedure removes endothelium but does not affect the ability of vascular smooth muscle to contract or relax ( fig. 1 2 (pH = 7.4). Two stainless steel hooks passed through its lumen suspended in each ring. One clip was anchored to the bottom of the organ chamber, and the other was connected to a strain gauge for measurement of isometric force (Grass FTO3, Grass Instrument Company, Quincy, Massachusetts). The rings were placed at the optimal point of their length-tension relation by progressively stretching them until the basal applied tension was 10 grams. In all experiments, the presence or absence of endothelium was confirmed determining the relaxing response to acetylcholine (10 -6 M) in rings contracted with potassium ions (20 mM) 14, 15 . After optimal tension was achieved, the arterial segments were allowed to equilibrate for 30-45 minutes before administration of drugs. The time between the treatment with indomethacin, NO-synthase inhibitors, vasopressin antagonist, L-arginine, D-arginine, and the beginning of the prostaglandin F 2α contraction was also 30-45 minutes. The time between 2 different concentrations of arginine vasopressin during the concentration-response curve was around 3 minutes. After prostaglandin F 2α contraction was stable, 3 kinds of experiments were performed: Experiment 1 -Eighteen coronary pairs (with and without endothelium) were exposed to a single high concentration of vasopressin (10 ] vasopressin, acetate salt, vascular segments were contracted with prostaglandin F 2α and then exposed to increasing concentrations of vasopressin.
Results are expressed as mean ± SEM. In all experiments, "n" refers to the number of animals from which blood vessels were taken. In segments contracted with prostaglandin F 2α , responses are expressed as percent changes from the contracted levels. Statistical evaluation of data was performed with the Student t test for either paired or unpaired observations. Values were considered statistically significant when P was less than 0.05.
Results
Coronary artery segments with and without endothelium exhibited comparable contraction to prostaglandin F 2α (2 x 10 -6 M), 5.05±0.86 and 4.72±1.80 grams, respectively, for arteries with and without endothelium (n = 6).
Experiment 1 -After contraction to prostaglandin was stable, administration of a high concentration of vasopres- sin (10 -6 M) caused a significant transient relaxation in arteries with endothelium and no change in tension in arteries without endothelium ( fig. 2) . If the concentration of vasopressin in the organ bath was then doubled in a cumulative manner, after 3-4 minutes, no additional endotheliumdependent vasodilatory response could be elicited; only vasoconstriction was apparent (n=3, data not shown). The endothelium-dependent vasodilator response to vasopressin in arterial segments, contracted with prostaglandin F 2α , could be inhibited by incubating the arterial segments with Ng-monomethyl-L-arginine (L-NMMA, 10 M) caused no significant change in tension of quiescent coronary arterial segments with or without endothelium. When arterial segments that had been exposed to vasopressin were washed, contracted with prostaglandin F 2α , and again exposed to the compound, transient endotheliumdependent relaxation was again observed (n=3, data not shown). The elapsed time between the 2 injections was the same 30-40 minutes, because indomethacin was added again to the coronary bath.
Experiment 3 -If vasopressin was added in a cumulative manner to the organ chamber, the endothelium-dependent relaxation to the compound was masked (fig. 4) . Indeed, when the concentration of vasopressin was gradually increased in the organ bath, coronary artery segments with and without endothelium did not exhibit any significant difference between the injections of vasopressin. However, if, after being exposed to a high concentration of vasopressin (10 Segments of left circumflex coronary artery, with and without endothelium, were suspended in organ chambers to measure isometric force. Segments were contracted with prostaglandin F 2α (2 x 10 -6 M). When the contraction to prostaglandin was stable, the vessels were exposed to vasopressin (10 -6 M)(top trace). Endothelium-dependent vasodilation to vasopressin could be inhibited by treating the vascular segments with L-NMMA (10 -5 M)(middle trace). The inhibitory effect of L-NMMA could be reversed by addition of L-arginine (10 -4 M)(bottom trace). caused transient, endothelium-dependent relaxation of arterial segments with endothelium. The complete concentration response curve lasted around 25 to 30 minutes, because the time observed among the increased concentration of vasopressin was around 3 minutes. The progressive increase in arterial tone was secondary to vasopressin action and was not dependent on the experimental time.
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Discussion
It is relevant to include a comment about the nomenclature of the vasopressin receptors; if the prevalent rules were applied, the names of these receptors ought to be V 1 (V 1 a), V 2 and V 3 (V 1 b), with the V 1 and V 3 receptors modifying phospholipase activity and the V 2 receptor regulating adenylyl cyclase (AC) activity, as is the case for the muscarinic receptors. The meeting of seasoned investigators who must agree on the adoption of these rules has not yet taken place, and therefore the original names are still maintained; the change has been left for the new millennium 16 . Vasopressin effects on coronary arteries have already been reported in many species. In canine and cat coronary arteries, vasopressin elicits endothelium-dependent vasodilatation in large vessels and vasoconstriction in resistance vessels 1, [17] [18] [19] . In other species (rabbit, rat, goat, and human), vasopressin induces a V 1 receptor-mediated vasoconstriction, eventually modulated by endothelial NO [20] [21] [22] [23] [24] . Pure vasodilatation seems to occur in isolated monkey coronary arteries via endothelium V 1 receptors and NO release 25 . In the present experiment, vasopressin induced transient, endothelium-dependent relaxation of the epicardial canine coronary artery, which was prevented by pretreating the vascular segments with Ng-monomethyl-L-arginine or NG-nitro-L-arginine, 2 inhibitors of nitric oxide synthesis from L-arginine 26, 27 . The finding that the inhibition of vasodilatation by L-NMMA could be reversed by exogenous Larginine emphasizes the specificity of the blockers for the Larginine pathway 28 . This relaxation was also reversibly inhibited by d(CH 2 ) 5 Try(Me) arginine vasopressin, suggesting that the vasodilator action is mediated by vasopressin V 1 -receptors on the endothelium [29] [30] [31] . Thus, we conclude that vasopressin acts on endothelial cell V 1 receptors to stimulate the production of nitric oxide from L-arginine, and then mediates cyclic-GMP-dependent relaxation of the underlying vascular smooth muscle 32 . Similar conclusions were obtained in experiments performed with pulmonary canine arteries 33 , monkey isolated coronary arteries 25 canine brain stem arteries 34 , and in vivo experiments studying vasopressin in anesthetized goats 23 . When vasopressin was added in a cumulative manner starting at a very low concentration, the endotheliumdependent vasodilator effect was masked. Two possible speculative explanations for this observation exist. First, it is possible that desensitization of the V 1 -receptor to activation by arginine vasopressin occurs at concentrations lower than the concentration necessary to induce EDNO production. Thus, when arginine vasopressin is given at a high concentration as a bolus injection, endothelial cell production of nitric oxide is stimulated to produce transient relaxation, but then the cell becomes refractory to further V 1 -receptor stimulation. The finding supports this hypothesis that additional injections of arginine vasopressin did not relax the vessel after the initial transient vasodilatation. However, in contrast with this theory is the observation that if blood vessels, which had been exposed to high concentrations of vasopressin, were quickly washed, contracted with prostaglandin F 2α and exposed to vasopressin (10 -6 M), they again exhibited transient, endothelium-dependent relaxation to the compound. One would not expect such a quick recovery of relaxation if the cell had truly become refractory to the compound. Indeed, by considering the modern concepts about the vasopressin receptors, it is impossible to rule out the role of desensitization. The ability of AVP to reduce the response of the V 1 a and V 2 receptors was first described in liver and kidney cells, respectively, while characterizing the activity of the natural receptors; the availability of the cDNAs encoding the receptors made it possible to identify some biochemical details of this desensitization by the use of transfected cells. Desensitization of the V1aR is fast and is accompanied by sequestration of receptors inside the cell in tissues and transfected cells. AVP-promoted phosphorylation of the V1aR analyzed in transfected cells reached maximum values immediately after agonist binding, and the phosphates were removed rapidly from the protein with a t1/2 of 6 minutes, while disappearance of the receptor from the cell surface after exposure to AVP had a t1/2 of 3 minutes. After the removal of ligand from the medium, recycling of the V1aR to the cell surface was efficient and complete in about 60 minutes 16 . Another possibility is that the onset of the constrictor action of vasopressin comes before the stimulated production of EDNO. Indeed, if the vasoconstrictive action of vasopressin occurred at a concentration below that which induces EDNO formation, vasoconstriction would be expressed at low vasopressin concentrations and might completely mask the vasodilatory action of EDNO stimulated by higher concentrations of vasopressin. The finding supports this theory that the maximal contraction to vasopressin (10 -5 M) was comparable in arterial segments with and without endothelium, an indication that vasopressin-mediated vasoconstriction can completely override cyclic GMP-mediated vasodilatation by vasopressin-stimulated EDNO production. Such a hypothesis is also consistent with studies demonstrating that the maximal tension developed to arginine vasopressin in the canine cerebral artery was unaffected by the presence or absence of an intact endothelium 35 . Interestingly, the vasorelaxation effect observed by using single vasopressin doses was no longer observed when the concentration response curve to vasopressin was tested. A small vasoconstrictor effect appeared in this condition instead. Despite the fact that the present results are mostly confirmatory of the literature, it clearly shows the endothelium-dependent (likely NO-dependent) vasorelaxation induced by vasopressin in large coronary arteries. The NO release elicited by single doses and the loss of the concentration-related effect deserves more investigation. Perhaps this fact is related to some functional characteristic of the V1-receptor as above discussed 16 . Vasopressin-mediated production of EDNO in the coronary circulation could have physiological implications 4 , by its selective vasoconstriction of regions with high O 2 supply/demand ratio serves to maintain vital tissue perfusion during periods of low cardiac output. If this were true, the stimulated production of EDNO by the coronary endothelium would also act to oppose ischemic events such as vasospasm and thrombosis through the antiaggregatory 36 and vasodilatory action 37 of the nitric oxide radical.
Finally, it is important to emphasize that studies on vasopressin vascular effects would be helpful because of its growing importance in human cardiopulmonary resuscitation 38, 39 . Coronary arteries probably never see such a high peptide 10 M after dehydration, surgical stress, or in pathological conditions.
